Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Enzyme replacement therapy (recombinant adenosine deaminase)

Revcovi (elapegademase-lvlr)

An approved treatment for Severe Combined Immunodeficiency.

FDA Approved (2018)by Chiesi USA
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2018

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Elapegademase-lvlr wherever you encounter it, plus the key facts at a glance.

Generic name
Elapegademase-lvlr
Brand name
Revcovi
Development code
EZN-2279
Drug class
Enzyme replacement therapy (recombinant adenosine deaminase)
Manufacturer
Chiesi USA
How it's taken
Injection into a muscle, one or more injections a week

An injection into a muscle that replaces adenosine deaminase, the enzyme missing in ADA-SCID, one genetic form of severe combined immunodeficiency.

  • Revcovi is approved for children and adults with ADA-SCID only, not for other types of SCID[1].
  • The FDA approved it on October 5, 2018[2], and its label carries no boxed warning.
Follow Revcovi by email

We'll email you when Revcovi's FDA label changes, when the FDA acts on it, and when new trials for Severe Combined Immunodeficiency open. Unsubscribe anytime.

You'll get, for Severe Combined Immunodeficiency:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Elapegademase-lvlr fits

Revcovi (elapegademase-lvlr) replaces the missing ADA enzyme in children and adults with ADA-SCID, and Chiesi describes it as the only FDA-approved enzyme replacement therapy for ADA-SCID[11].

  • A 2019 consensus paper from ADA-SCID specialists in the Journal of Allergy and Clinical Immunology advises that every patient with ADA-SCID start on enzyme replacement first, then move to a definitive treatment[6].
  • The 2019 consensus paper names 2 equal first choices for ADA-SCID: a stem cell transplant from a matched sister, brother or other family member, or gene therapy using the patient's own corrected stem cells[6].
  • Strimvelis, a gene therapy for ADA-SCID, has been authorized in the European Union since May 26, 2016 for patients without a suitable matched related donor[7].
  • The FDA's list of approved cellular and gene therapy products, current as of October 30, 2026, includes no gene therapy for ADA-SCID, and a UCLA gene therapy study (NCT05432310) is active but no longer recruiting[8][5].
  • Revcovi's approval rested on 2 small single-arm studies in ADA-SCID with 10 patients in all, and the label reports no trial comparing it with transplant or gene therapy[1].
  • Families can ask their immunologist whether a matched donor, gene therapy or a trial fits their child, and how long enzyme replacement is planned to continue.

How Elapegademase-lvlr works

In ADA-SCID, changes in both copies of the ADA gene leave the body short of an enzyme called adenosine deaminase[9]. That enzyme normally breaks down adenosine and deoxyadenosine, leftovers from the body's normal turnover of DNA and cells. Without it, these substances and the related deoxyadenosine nucleotides (dAXP) build up, and the label explains that high adenosine levels contribute to the death of developing T cells and block their maturing, which leaves very few lymphocytes, the white blood cells that fight infection[1].

Revcovi supplies the missing enzyme from outside the body. Its enzyme follows the cow (bovine) ADA sequence, is made in E. coli bacteria and is attached to polyethylene glycol (PEG)[1]. The label reports that treatment lowers the toxic nucleotides and raises lymphocyte numbers, and says immune function generally improves after 2 to 6 months of therapy and keeps maturing after that[1].

Side effects and safety

What patients report
Label warnings
  • Injection site bleeding with low platelets. Revcovi is injected into a muscle, so the label says to use it with caution when platelet counts are low and not to use it when they are severely low
  • Delay before the immune system improves. the timing and degree of immune improvement vary, so the label says infection precautions continue until immune function has improved
  • Antibodies against the enzyme. people who took Adagen before may make antibodies to Revcovi; a lasting fall in trough plasma ADA activity below 15mmol/hr/L calls for antibody testing
  • Reactions reported with Adagen. after approval, Adagen, an older enzyme of the same class, was linked to hemolytic anemia, high or low platelet counts, injection site redness, hives and lymphomas, which the label says may also occur with Revcovi
Most common in trials
coughvomiting
What gets monitored
  • Trough plasma ADA activity, aiming for at least 30mmol/hr/L: every 2 weeks for people new to enzyme therapy and every 4 weeks for people switching from Adagen during the first 8 to 12 weeks, then every 3 to 6 months
  • Trough red blood cell dAXP, kept below 0.02mmol/L from 2 months on and checked at least twice a year
  • Total and subset lymphocyte counts: every 4 to 8 weeks for up to 1 year in people new to enzyme therapy, then every 3 to 6 months
  • Antibody testing when trough ADA activity stays below 15mmol/hr/L
Report a suspected reaction to Chiesi USA at 1-888-661-9260, or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
In context

Revcovi has no boxed warning and no contraindications[1]. The label carries 2 warnings. Because Revcovi is injected into a muscle, it can cause bleeding at the injection site in people with low platelet counts, and it should not be used when platelets are severely low. Since immune function takes time to improve after treatment starts, the label says infection precautions continue until it does[1].

In the US study of 6 people aged 8 to 37 who switched from Adagen, the most common side effects were cough (3 of 6, or 50%) and vomiting (2 of 6, or 33%); 1 person stopped because of injection site pain linked to an earlier formulation that was later changed[1]. In the Japanese study of 4 patients aged 3.4 months to 25 years, an infant died of cytomegalovirus (CMV) pneumonitis and respiratory failure, and 1 patient had neutropenia, a low count of infection-fighting neutrophils, reported as a serious adverse reaction[1].

People who took Adagen before may develop antibodies to Revcovi, which is why ADA activity is tracked during treatment[1]. After approval, Adagen was linked to hemolytic anemia, autoimmune hemolytic anemia, high or low platelet counts, injection site redness, hives and lymphomas, and the label says these may also be seen with Revcovi[1].

Revcovi has not been studied in pregnancy; the label notes 2 reports of successful pregnancy and delivery in women with ADA-SCID treated with Adagen and recommends closer monitoring of mother and baby[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Elapegademase-lvlr

Revcovi is injected into a muscle (intramuscular injection) only[1]. For people new to enzyme therapy, the starting dose is 0.4mg/kg a week, based on ideal or actual body weight, whichever is greater, split into 2 injections of 0.2mg/kg twice a week for at least 12 to 24 weeks until the immune system recovers; after that the dose may be lowered step by step while blood tests stay on target[1].

For people switching from Adagen, the starting dose is at least 0.2mg/kg once a week, or a dose converted from the Adagen dose when that dose was above 30U/kg a week[1]. The doctor sets the long-term dose and schedule for each person from trough ADA activity, dAXP levels and clinical status[1]. Revcovi comes as a single-dose vial holding 2.4mg in 1.5mL, kept in the refrigerator and never frozen or shaken, warmed at room temperature for 30 minutes and drawn into a polypropylene syringe; the injection site is changed from time to time[1].

Chiesi's patient brochure says Revcovi can be given at home after a doctor shows how, or in the doctor's office[11].

Availability and cost

No generic available

Only available as the brand-name product.

Why it costs what it costs

A lifelong enzyme replacement biologic for an ultra-rare disease. The label gives no price. Chiesi Total Care offers a copay program for commercially insured patients and a free-drug program for uninsured or underinsured patients who meet its income limit.

Help paying for Revcovi

With private insurance, the drugmaker's copay card can lower what you pay for Revcovi. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. The charity fund for Severe Combined Immunodeficiency was not taking new applications on November 17, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Revcovi (Elapegademase-lvlr)
Some details not published
  • Copay help

    Revcovi Copay Program: people with commercial insurance and a prescription for an FDA-approved use may pay as little as $0. Must be enrolled in Chiesi Total Care and live in the US or a US territory. Not valid with Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, VA, DoD, state prescription assistance plans or other government-funded plans. Patients in some states may not be eligible. No annual maximum is published; the terms say restrictions, including monthly maximums, may apply. Eligibility must be renewed by December 31 each year.

    For: private insurance · source
  • Free medicine program

    Patient Assistance Program: Revcovi at no cost for people who are uninsured or underinsured, enrolled in Chiesi Total Care, with annual household income that does not exceed 500% of the Federal Poverty Level, living in the US or a US territory and not receiving benefits from a federal or state-funded plan. Proof of income such as W2 forms, pay stubs or tax returns is required.

    For: no insurance, underinsured · source
  • Insurance and case manager help

    A Patient Service Coordinator, benefits verification, prior authorization and appeals help, delivery of the medicine, help with administration, storage and disposal questions, and access to a pharmacist and nursing support. Chiesi says it may give non-financial help to patients with or without drug coverage. Fax 1-866-272-7079.

    The official page does not say who qualifies. Ask the program. · source

Good to know: Terms read on chiesitotalcare.com/revcovi/patients-caregivers/ and the Chiesi Total Care terms PDF (PP-G-0834 V2.0 2024) on November 14, 2026. Hours are Monday to Friday, 7 AM to 6 PM Central Time. The terms PDF says only commercially insured patients can get financial support, while the patient page offers free drug to uninsured or underinsured patients under 500% FPL; both exclude government-funded plans. No copay annual maximum is published.

Checked on the drugmaker's official pages on November 14, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Severe Combined Immunodeficiency

  • From a charity · The Assistance Fund
    Primary Immunodeficiency fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 17, 2026.

Every program and charity fund for Severe Combined Immunodeficiency →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Access and eligibility

Manufacturer
Chiesi USA
Eligibility requirement

Approved for children and adults with adenosine deaminase severe combined immune deficiency (ADA-SCID)[1]. Revcovi is not approved for other genetic types of SCID, such as X-linked SCID. The label says safety and efficacy are established in children, and Revcovi was not studied in people 65 and older[1].

Source: Chiesi Total Care

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Clinical trial results

Approval rested on 2 small open-label, single-arm studies with 10 patients in all and no comparison group[1]. Study 1 (NCT01420627), run in the US, switched 6 people aged 8 to 37 from Adagen to Revcovi[1][4]. On Revcovi at a normalized dose of 0.2mg/kg a week, mean trough plasma ADA activity was 34.3mmol/hr/L, against 14.2mmol/hr/L on Adagen at 30U/kg a week in the same patients[1].

The 3 patients treated for more than 135 weeks kept red blood cell dAXP at or below 0.02mmol/L at every check but 1, and their lymphocyte counts reached peaks of about 1.5 to 3 times the Adagen levels[1]. Study 2, run in Japan, treated 4 patients aged 3.4 months to 25 years. All 4 reached and kept dAXP at or below 0.02mmol/L through the 21-week treatment phase, and 3 reached ADA activity above 15mmol/hr/L during the maintenance period; 1 infant died of CMV pneumonitis[1].

Development history

Revcovi was developed under the code EZN-2279 and tested in a US study sponsored by Leadiant Biosciences, which completed in May 2019[4]. The FDA approved Revcovi on October 5, 2018 under BLA 761092[2]. Revcovi followed Adagen (pegademase bovine), an older ADA enzyme approved in 1990 that Drugs@FDA now lists as discontinued[3]. Chiesi USA lists acquiring the rights to Revcovi in November 2020[10], and the current label names Chiesi USA as the manufacturer[1].

Ask anything about Elapegademase-lvlr
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Severe Combined Immunodeficiency trials

Common questions about Elapegademase-lvlr

▸What is Elapegademase-lvlr (Revcovi)?

An injection into a muscle that replaces adenosine deaminase, the enzyme missing in ADA-SCID, one genetic form of severe combined immunodeficiency. Revcovi is approved for children and adults with ADA-SCID only, not for other types of SCID[1]. The FDA approved it on October 5, 2018[2], and its label carries no boxed warning.

▸How does Elapegademase-lvlr work?

In ADA-SCID, changes in both copies of the ADA gene leave the body short of an enzyme called adenosine deaminase[9]. That enzyme normally breaks down adenosine and deoxyadenosine, leftovers from the body's normal turnover of DNA and cells. Without it, these substances and the related deoxyadenosine nucleotides (dAXP) build up, and the label explains that high adenosine levels contribute to the death of developing T cells and block their maturing, which leaves very few lymphocytes, the white blood cells that fight infection[1]. Revcovi supplies the missing enzyme from outside the body. Its enzyme follows the cow (bovine) ADA sequence, is made in E. coli bacteria and is attached to polyethylene glycol (PEG)[1]. The label reports that treatment lowers the toxic nucleotides and raises lymphocyte numbers, and says immune function generally improves after 2 to 6 months of therapy and keeps maturing after that[1].

▸What are the side effects of Elapegademase-lvlr?

Revcovi has no boxed warning and no contraindications[1]. The label carries 2 warnings. Because Revcovi is injected into a muscle, it can cause bleeding at the injection site in people with low platelet counts, and it should not be used when platelets are severely low. Since immune function takes time to improve after treatment starts, the label says infection precautions continue until it does[1]. In the US study of 6 people aged 8 to 37 who switched from Adagen, the most common side effects were cough (3 of 6, or 50%) and vomiting (2 of 6, or 33%); 1 person stopped because of injection site pain linked to an earlier formulation that was later changed[1]. In the Japanese study of 4 patients aged 3.4 months to 25 years, an infant died of cytomegalovirus (CMV) pneumonitis and respiratory failure, and 1 patient had neutropenia, a low count of infection-fighting neutrophils, reported as a serious adverse reaction[1]. People who took Adagen before may develop antibodies to Revcovi, which is why ADA activity is tracked during treatment[1]. After approval, Adagen was linked to hemolytic anemia, autoimmune hemolytic anemia, high or low platelet counts, injection site redness, hives and lymphomas, and the label says these may also be seen with Revcovi[1]. Revcovi has not been studied in pregnancy; the label notes 2 reports of successful pregnancy and delivery in women with ADA-SCID treated with Adagen and recommends closer monitoring of mother and baby[1].

▸How is Elapegademase-lvlr taken?

Revcovi is injected into a muscle (intramuscular injection) only[1]. For people new to enzyme therapy, the starting dose is 0.4mg/kg a week, based on ideal or actual body weight, whichever is greater, split into 2 injections of 0.2mg/kg twice a week for at least 12 to 24 weeks until the immune system recovers; after that the dose may be lowered step by step while blood tests stay on target[1]. For people switching from Adagen, the starting dose is at least 0.2mg/kg once a week, or a dose converted from the Adagen dose when that dose was above 30U/kg a week[1]. The doctor sets the long-term dose and schedule for each person from trough ADA activity, dAXP levels and clinical status[1]. Revcovi comes as a single-dose vial holding 2.4mg in 1.5mL, kept in the refrigerator and never frozen or shaken, warmed at room temperature for 30 minutes and drawn into a polypropylene syringe; the injection site is changed from time to time[1]. Chiesi's patient brochure says Revcovi can be given at home after a doctor shows how, or in the doctor's office[11].

▸Is Elapegademase-lvlr FDA approved?

Yes, for ADA-SCID only. The FDA approved Revcovi on October 5, 2018 for children and adults with adenosine deaminase severe combined immune deficiency.

Other SCID types: Revcovi is not approved for SCID caused by other genes, such as X-linked SCID.

How it is given: an injection into a muscle, one or more injections a week.

Source: Revcovi prescribing information

▸How is Revcovi dosed for ADA-SCID?

For people new to enzyme therapy, Revcovi starts at 0.4mg/kg a week, split into 2 injections of 0.2mg/kg into a muscle[1].

How long: at least 12 to 24 weeks at that dose, until the immune system recovers.

After that: the dose may be lowered step by step while blood tests stay on target.

Switching from Adagen: the starting dose is at least 0.2mg/kg once a week, or a converted dose when the Adagen dose was above 30U/kg a week.

Source: Revcovi prescribing information

▸What blood tests are needed on Revcovi?

The label tracks 3 things: trough ADA activity in plasma, dAXP in red blood cells and lymphocyte counts[1].

ADA activity: target at least 30mmol/hr/L, checked every 2 to 4 weeks for the first 8 to 12 weeks, then every 3 to 6 months.

dAXP: kept below 0.02mmol/L from 2 months on, checked at least twice a year.

Lymphocytes: every 4 to 8 weeks for up to 1 year in people new to enzyme therapy, then every 3 to 6 months.

When to test for antibodies: if trough ADA activity stays below 15mmol/hr/L.

Source: Revcovi prescribing information

▸What replaced Adagen for ADA-SCID?

Revcovi is the ADA enzyme replacement now sold in the US, and Drugs@FDA lists Adagen (pegademase bovine) as discontinued[3].

Switching: the Revcovi label gives a starting dose and a conversion formula for people moving from Adagen.

Antibodies: people who took Adagen may make antibodies to Revcovi, which is one reason ADA activity is checked.

Source: Revcovi prescribing information and Drugs@FDA

▸Is there help paying for Revcovi?

Chiesi Total Care offers a copay program for commercially insured patients and free medicine for some uninsured or underinsured patients[12].

Copay: people with commercial insurance may pay as little as $0.

Free drug: for people who are uninsured or underinsured with household income no higher than 500% of the Federal Poverty Level.

Not eligible for financial help: people on Medicare, Medicaid, VA, TRICARE or other government plans.

Phone: 1-866-272-7078, Monday to Friday, 7AM to 6PM Central Time.

Source: Chiesi Total Care

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Chiesi USA, Inc. via DailyMed · 2026-05-31. REVCOVI- elapegademase-lvlr injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c073f84-cdd0-40e4-b3a9-172687267f28
  2. U.S. Food and Drug Administration · 2018-10-05. REVCOVI approval history, BLA 761092. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761092
  3. U.S. Food and Drug Administration, openFDA · 1990-03-21. ADAGEN (pegademase bovine), BLA 019818, marketing status Discontinued. https://api.fda.gov/drug/drugsfda.json?search=application_number:"BLA019818"
  4. ClinicalTrials.gov. EZN-2279 in Patients With ADA-SCID. https://clinicaltrials.gov/study/NCT01420627
  5. ClinicalTrials.gov. Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector. https://clinicaltrials.gov/study/NCT05432310
  6. Journal of Allergy and Clinical Immunology (Kohn et al., PMID 30194989) · 2019-03. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. https://pubmed.ncbi.nlm.nih.gov/30194989/
  7. European Medicines Agency. Strimvelis | European Medicines Agency (EMA). https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis
  8. U.S. Food and Drug Administration · 2026-10-30. Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
  9. National Library of Medicine, MedlinePlus. Adenosine deaminase deficiency: MedlinePlus Genetics. https://medlineplus.gov/genetics/condition/adenosine-deaminase-deficiency/
  10. Chiesi USA. Our Legacy | Chiesi USA, Inc. Website. https://www.chiesiusa.com/our-company/our-legacy/
  11. Chiesi USA. REVCOVI Patient Brochure. https://resources.chiesiusa.com/Revcovi/REVCOVI_Patient_Brochure.pdf
  12. Chiesi USA. Revcovi® support for Patients & Caregivers: Chiesi Total Care℠. https://www.chiesitotalcare.com/revcovi/patients-caregivers/
  13. Chiesi USA · 2024. REVCOVI CTC Terms and Conditions. https://resources.chiesiusa.com/Revcovi/REVCOVI_CTC_Terms_and_Conditions.pdf

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Revcovi by email

We'll email you when Revcovi's FDA label changes, when the FDA acts on it, and when new trials for Severe Combined Immunodeficiency open. Unsubscribe anytime.

You'll get, for Severe Combined Immunodeficiency:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site